Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · GeoVax Labs, Inc. (GOVX)

GeoVax Labs faces Nasdaq delisting; hearing set for October 13, 2026

Negative Impact 4 of 5 legal/regulatory Written later

GGeoVax Labs said it has requested a Nasdaq Hearings Panel appeal of a delisting determination it received on August 27, 2026, over the minimum bid price requirement, with a hearing scheduled for October 13, 2026. The company says its stock should keep trading on the Nasdaq Capital Market under GOVX at least through that period, and it reaffirmed its focus on the GEO-MVA vaccine program and Gedeptin.

Key points

  • Nasdaq delisting determination received August 27, 2026, relating to the minimum bid price requirement under Listing Rule 5550(a)(2)
  • Hearing before the Nasdaq Hearings Panel scheduled for October 13, 2026
  • Hearing request has stayed any suspension or delisting action; GOVX expected to keep trading at least through that period
  • GeoVax plans to present a compliance plan to regain and maintain listing standards

The filing

CompanyGeoVax Labs, Inc. (GOVX)
Form8-K, current report
Filed with the SECSep 10, 2026, 4:35 PM ET
Accession number0001437749-26-030085

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:29 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 10, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.